🇺🇸 FDA
Patent

US 11986515

Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)

granted A61KA61K35/761A61K38/465

Quick answer

US patent 11986515 (Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)) held by REGENXBIO INC. expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENXBIO INC.
Grant date
Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K35/761, A61K38/465, A61K45/06, A61K48/005